DLBCL diagnosis is supported by the presence of (BCL2 expression, Ki‐67 rate < 90%, no cytogenetic evidence of MYC translocation, and BCL2 and/or BCL6 rearrangement). This evidence concerns the gene MYC and diffuse large B-cell lymphoma.